Skip to main content

Supporting allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia


Caribou Biosciences


TAP Partner

Project Term: February 28, 2021 - TBD

In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia." LLS is supporting the preclinical development of CB-012, Caribou’s third allogeneic CAR-T cell therapy, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia (AML). CD371 is expressed on the surface of AML tumor cells and leukemic stem cells, but it is not expressed on normal hematopoietic stem cells, which makes it a compelling target for the treatment of AML. Caribou is applying their genome editing expertise to armor the CB-012 CAR-T product in order to drive persistence and seek maximum patient benefit.


Lay Abstract

For additional information, please visit

Therapy Acceleration Program
To All Projects